The plant pest apple proliferation phytoplasma was detected in an apple orchard near Kentville, Nova Scotia, Canada, reported the Animal and Plant Health Inspection Service. The Canadian Food Inspection Agency has placed the orchard under quarantine, it said. The pest, which is considered “one of the most critical diseases of apple trees,” was found on Pacific Gala apple trees imported into Canada from the U.S., APHIS said.
The Foreign Trade Zones Board issued the following notices for April 3:
The Court of International Trade remanded the final injury determination from the antidumping and countervailing duty investigations of multilayered wood flooring from China, finding the International Trade Commission failed to account for the effect of the housing downturn and financial crisis on the domestic wood flooring industry. The court also found fault with the ITC’s refusal to include domestic hardwood plywood producers in its injury investigation, and its lack of explanation of whether imports from China were the “but-for” cause of injury.
A listing of recent antidumping and countervailing duty messages from the International Trade Administration posted to CBP's website April 2, along with the case number(s) and CBP message number, is provided below. The messages are available by searching for the listed CBP message number at addcvd.cbp.gov. (CBP occasionally adds backdated messages without otherwise indicating which message was added. ITT will include a message date in parentheses in such cases.)
Mexico's Diario Oficial of March 21, lists notices from the Secretary of the Economy as follows:
The International Trade Commission is publishing notices in the April 2 Federal Register on the following AD/CV injury, Section 337 patent, and other trade proceedings (any notices that warrant a more detailed summary will appear in another ITT article):
The International Trade Commission is asking for comments by April 11 on public interest issues raised by ResMed’s Section 337 patent complaint on sleep-disordered breathing treatment systems and components (see 13040201). According to the underlying petition, the products are used in the treatment of obstructive sleep apnea by delivering pressurized air to the user to keep that user’s breathing passages open during sleep. ResMed alleges that Apex Medical and Drive Medical Design & Manufacturing manufacture and import breathing treatment systems that infringe its patents. ResMed is requesting cease and desist and limited exclusion orders against the respondents.
ResMed filed a Section 337 complaint with the International Trade Commission March 28, alleging imports of sleep-disordered breathing treatment systems and components from Apex Medical and Drive Medical Design & Manufacturing infringe its patents. The products are used in the treatment of obstructive sleep apnea by delivering pressurized air to the user to keep that user’s breathing passages open during sleep, the petition for investigation said. According to Resmed, Apex makes infringing breathing treatment systems abroad, and imports them into the U.S. through its affiliate Apex Medical USA. Medical Depot, which does business as Drive Medical Design & Manufacturing, also imports infringing breathing treatment systems it buys from Apex Medical, the complaint alleged. ResMed is requesting the ITC issue limited exclusion and cease and desist orders against the proposed respondents.
The International Trade Administration published notices in the April 2 Federal Register on the following AD/CV duty proceedings (any notices that announce changes to AD/CV duty rates, scope, affected firms, or effective dates will be detailed in another ITT article):
The Environmental Protection Agency set exemptions for tolerances for residues of styrene-ethylene-propylene block copolymer (here); and castor oil, polymer with adipic acid, linoleic acid, oleic acid, and ricinoleic acid (here), when used as inert ingredients in pesticide formulations. The exemptions, which are effective April 3, eliminate the need to set maximum residue limits (MRLs) for the chemicals, EPA said. Objections to the EPA’s final rule are due by June 3.